TransHERA: The Complete Guide to the Breast Cancer Clinical Trial That Changed Treatment Standards

TransHERA: The Complete Guide to the Breast Cancer Clinical Trial That Changed Treatment Standards

Quick Facts

DetailInfo
Study nameTransHERA
Full nameA Phase III Study of Tucatinib or Placebo in Combination With Trastuzumab and Capecitabine in Patients With HER2+ Locally Advanced or Metastatic Breast Cancer
Drug investigatedTucatinib (brand name: Tukysa)
Drug developerSeagen (acquired by Pfizer in 2023)
PhasePhase III — the highest level of clinical trial before regulatory approval
Patient populationAdults with metastatic or locally advanced HER2-positive breast cancer
Trial combinationTucatinib or placebo + trastuzumab + capecitabine
Primary endpointProgression-free survival (PFS)
Key secondary endpointsOverall survival (OS), overall response rate (ORR), intracranial response rate
Notable focusBrain metastases — a particularly hard-to-treat complication in HER2+ breast cancer
Why it mattersDemonstrated benefit for patients who had already received prior HER2-directed therapy
Related studyHER2CLIMB — the predecessor trial whose results supported tucatinib’s initial approval

Introduction: Why This Trial Matters

One of the most actively researched subtypes of breast cancer is HER2-positive breast cancer. Human epidermal growth factor receptor 2, or HER2 for short, is a protein that stimulates cell division. When a tumour overexpresses HER2, it tends to grow faster and spread more readily than HER2-negative cancers.

Fortunately, HER2 is a target as well. Drugs designed to block HER2 signalling have transformed the treatment landscape over the past two decades, turning what was once one of the most feared breast cancer subtypes into one of the most treatable.

But treatment eventually fails for most patients with metastatic disease. Tumours adapt. HER2-directed therapies stop working. And when cancer spreads to the brain — which happens more often in HER2-positive breast cancer than in many other subtypes — treatment becomes dramatically more challenging.

The TransHERA study was designed to address exactly that moment: when earlier HER2-directed therapy has already been given, when disease is advanced, and when better options are urgently needed. Its investigation of tucatinib — a small molecule tyrosine kinase inhibitor — aimed to determine whether adding this targeted agent could meaningfully extend the time before disease progressed.

See also “Sorayabanks5: What a Username Tells Us About Digital Identity, Personal Branding, and the Power of an Online Name“

Understanding HER2-Positive Breast Cancer

Before exploring the trial itself, it helps to understand the biology it was addressing.

Breast cells have a receptor called HER2 on their surface. In normal tissue, HER2 plays a regulated role in cell growth. In HER2-positive breast cancer, the gene encoding HER2 is amplified — essentially, there are too many copies of the gene, which leads to too much HER2 protein on the cell surface, which drives uncontrolled cell growth.

Approximately 15 to 20 percent of breast cancers are HER2-positive. For many years, before targeted HER2 therapy existed, this subtype carried a significantly worse prognosis than HER2-negative disease. The development of trastuzumab (Herceptin) in the late 1990s was transformative — a monoclonal antibody that binds directly to HER2 and inhibits its function, allowing the immune system to attack HER2-positive cells more effectively.

Since then, the HER2-positive treatment landscape has expanded considerably. Pertuzumab, ado-trastuzumab emtansine (T-DM1), trastuzumab deruxtecan (T-DXd), neratinib, and lapatinib have all entered practice at various stages of treatment. Each new agent has pushed survival outcomes further in a disease where survival measured in months has gradually extended to years for many patients.

However, most patients still have no chance of recovery from metastatic HER2-positive breast cancer. The challenge is to keep extending progression-free survival, overall survival, and quality of life through a sequence of effective therapies as each one eventually loses its effectiveness.

What Is Tucatinib and How Does It Work

Tucatinib is a small molecule — specifically, a tyrosine kinase inhibitor — that works differently from the monoclonal antibodies like trastuzumab that dominate HER2-directed therapy.

Where trastuzumab binds to the outside of the HER2 receptor, tucatinib enters the cell and blocks the kinase domain — the part of the HER2 protein inside the cell that sends growth signals downstream. By blocking this internal signalling function, tucatinib can inhibit HER2 activity even when surface-level binding is not fully effective.

What makes tucatinib particularly notable in the HER2 treatment landscape is its high selectivity. Many tyrosine kinase inhibitors that target HER2 also target other related receptors — particularly EGFR (epidermal growth factor receptor, also called HER1). Blocking EGFR causes its own toxicity profile, particularly skin rash and diarrhoea. Tucatinib is highly selective for HER2 over EGFR, which means it can achieve meaningful HER2 inhibition with a more manageable toxicity profile than less selective alternatives.

There is another critically important feature of tucatinib that made it particularly compelling for the TransHERA population: it crosses the blood-brain barrier. The blood-brain barrier is a highly selective filtering system that protects the brain from many substances — including many cancer drugs. This creates a serious clinical problem in HER2-positive breast cancer, which has a relatively high rate of brain metastasis. Many HER2-directed therapies that work elsewhere in the body have limited activity in the brain simply because they can’t get there in sufficient concentrations. Tucatinib appears to penetrate the blood-brain barrier meaningfully, making it potentially active against intracranial disease.

The HER2CLIMB Foundation: What Came Before TransHERA

TransHERA built on the foundation established by HER2CLIMB — a pivotal Phase III trial that led to tucatinib’s initial approval.

HER2CLIMB enrolled patients with HER2-positive metastatic breast cancer who had received prior trastuzumab, pertuzumab, and T-DM1 — meaning they were heavily pretreated, with limited remaining standard options. The trial compared tucatinib plus trastuzumab plus capecitabine against placebo plus trastuzumab plus capecitabine.

The results were practice-changing. Tucatinib significantly extended progression-free survival compared to the control arm. Overall survival was also meaningfully improved. And in patients with brain metastases — a subgroup included in HER2CLIMB specifically because of tucatinib’s blood-brain barrier penetration — the benefit was particularly notable. The intracranial response rate and time to intracranial progression both favoured tucatinib over placebo.

Based on these results, the FDA approved tucatinib in combination with trastuzumab and capecitabine for HER2-positive metastatic breast cancer in patients who had received one or more prior anti-HER2-based treatments. The approval was granted in April 2020.

TransHERA asked a related but distinct question: does tucatinib provide meaningful benefit in patients who had received one prior line of HER2-directed therapy rather than three or more? In other words, could this combination benefit patients earlier in their treatment journey?

The TransHERA Trial Design

The TransHERA study was designed as a randomised, double-blind, placebo-controlled Phase III trial — the gold standard design for evaluating treatment efficacy.

Patients enrolled in TransHERA had HER2-positive locally advanced or metastatic breast cancer and had received prior treatment with trastuzumab and a taxane, but not prior treatment with other HER2-directed agents in the metastatic setting beyond those. This represented a different — and earlier — treatment population than HER2CLIMB.

Participants were randomly assigned to receive either tucatinib or placebo, in combination with trastuzumab and capecitabine. The primary endpoint was progression-free survival — the time from randomisation until disease progression or death.

Secondary endpoints included overall survival, overall response rate (the proportion of patients whose tumours shrank meaningfully), and critically, outcomes in the brain metastasis subgroup. Brain metastasis outcomes were a key secondary focus given tucatinib’s established intracranial activity from HER2CLIMB.

The double-blind design meant that neither patients nor their treating physicians knew which treatment arm each patient was in during the study. This prevents conscious and unconscious biases from affecting how treatment is delivered, how symptoms are assessed, and how outcomes are recorded.

Why Brain Metastases Are a Central Focus

One of the most important dimensions of the TransHERA study — and of tucatinib’s clinical development more broadly — is its attention to brain metastases.

Brain metastases are cancer cells that have spread from the original tumour to the brain. In HER2-positive metastatic breast cancer, the lifetime incidence of brain metastases is higher than in most other breast cancer subtypes — estimates range from 30 to 50 percent of patients with advanced HER2-positive disease developing brain involvement at some point.

Brain metastases represent a serious clinical challenge for several reasons. They can cause neurological symptoms — headaches, cognitive changes, seizures, focal weakness — that significantly affect quality of life. Standard treatments include surgery, whole-brain radiation, and stereotactic radiosurgery, but these have limitations and side effects of their own. And many systemic cancer drugs — drugs that circulate throughout the body — have limited ability to penetrate the blood-brain barrier in sufficient concentrations to control intracranial disease.

This is precisely why tucatinib’s apparent blood-brain barrier penetration was considered so clinically significant. If a HER2-directed drug can achieve meaningful concentrations in the brain, it has the potential to control or delay intracranial progression in ways that many other agents cannot. The intracranial response data from HER2CLIMB supported this hypothesis strongly enough that the TransHERA trial was designed with dedicated brain metastasis endpoints.

The Broader Context: HER2-Positive Breast Cancer Treatment in 2026

The TransHERA study fits into a treatment landscape that has changed dramatically in the years since tucatinib was first approved.

Trastuzumab deruxtecan (T-DXd, brand name Enhertu) has emerged as one of the most active agents ever studied in HER2-positive breast cancer, with response rates and survival outcomes that have reset expectations in the field. The DESTINY-Breast series of trials has established T-DXd as a preferred option in patients with previously treated HER2-positive metastatic breast cancer.

The relative positioning of tucatinib-based regimens and T-DXd-based regimens in the treatment sequence continues to evolve as data from multiple trials mature. TransHERA’s data contributes to this evolving picture by providing information about tucatinib’s activity in patients earlier in their treatment journey.

The ultimate goal — translating advances in metastatic disease back to earlier stages, where cure remains a possibility — continues to drive the field. Research into tucatinib in earlier treatment settings, including combination with other agents and in neoadjuvant and adjuvant contexts, reflects this broader ambition.

Final Words

The TransHERA study represents something genuinely important about how modern oncology research works at its best.

It built systematically on prior evidence — HER2CLIMB established that tucatinib works in heavily pretreated patients; TransHERA asked whether it works earlier. It addressed a clinically urgent population — patients with HER2-positive advanced breast cancer who need effective options at every stage of their treatment journey. And it took brain metastases seriously as a primary concern rather than an afterthought, designing the trial specifically to capture intracranial outcomes in a disease where brain involvement is a major source of morbidity and mortality.

The story of HER2-positive breast cancer over the past three decades is one of the most remarkable in oncology — a subtype that was once a feared diagnosis transformed into one where long-term survival with metastatic disease is a realistic expectation for many patients. TransHERA is one chapter in that ongoing story, contributing data that helps clinicians make better decisions for the patients in their care.

For patients, understanding clinical trials like TransHERA — what they test, why they’re designed the way they are, and what their results mean — is part of navigating a treatment landscape that is both complex and genuinely improving.

FAQs

1. What is the TransHERA study?

TransHERA is a Phase III randomised clinical trial evaluating tucatinib in combination with trastuzumab and capecitabine in patients with HER2-positive locally advanced or metastatic breast cancer who have received prior HER2-directed therapy. It builds on the earlier HER2CLIMB trial that established tucatinib’s initial clinical profile.

2. What is HER2-positive breast cancer?

HER2-positive breast cancer is a subtype in which the tumour overexpresses the HER2 protein — a receptor that drives cell growth. It accounts for approximately 15 to 20 percent of breast cancers and is treated with specific HER2-directed therapies including monoclonal antibodies and tyrosine kinase inhibitors.

3. What is tucatinib and how does it work?

Tucatinib (brand name Tukysa) is a highly selective tyrosine kinase inhibitor that blocks HER2’s internal signalling domain. It is highly specific for HER2 over the related EGFR receptor, which gives it a more manageable toxicity profile than less selective alternatives. It also penetrates the blood-brain barrier, making it potentially active against brain metastases.

4. What is the difference between TransHERA and HER2CLIMB?

HER2CLIMB enrolled heavily pretreated patients who had received three or more prior HER2-directed therapies (trastuzumab, pertuzumab, and T-DM1). TransHERA studied an earlier treatment population — patients who had received one prior HER2-directed therapy. Both used the same tucatinib-based combination regimen.

5. Why does TransHERA focus on brain metastases?

HER2-positive breast cancer has a relatively high rate of brain metastasis — an estimated 30 to 50 percent of patients with advanced disease develop brain involvement. Because tucatinib appears to cross the blood-brain barrier, capturing its intracranial activity was a specific clinical priority built into the TransHERA design.

6. What is progression-free survival (PFS) and why is it used as an endpoint?

Progression-free survival is the time from the start of treatment until disease progression (tumour growth or spread) or death. It is used as a primary endpoint because it can be measured earlier than overall survival and captures meaningful clinical benefit — a longer time before disease worsens directly affects patient quality of life.

7. Phase III clinical trials: what are they?

Phase III is the final large-scale testing stage before a drug can be considered for regulatory approval. Phase III trials typically involve hundreds or thousands of patients, are randomised (patients are randomly assigned to treatment or control arms), and are designed to definitively determine whether a new treatment is better than the current standard of care.

8. What is capecitabine and why is it part of the TransHERA combination?

Capecitabine is an oral chemotherapy drug that is converted in the body to fluorouracil — a standard chemotherapy agent. It is included in the tucatinib combination because preclinical evidence and earlier clinical work suggested that the combination of tucatinib, trastuzumab, and capecitabine produces synergistic antitumour activity beyond what any single agent achieves alone.

9. How does tucatinib’s selectivity for HER2 over EGFR matter clinically?

Less selective tyrosine kinase inhibitors that also block EGFR — such as lapatinib and neratinib — produce EGFR-related toxicities including skin rash and diarrhoea that can limit tolerability. Tucatinib’s high selectivity for HER2 reduces these toxicities, potentially allowing more patients to maintain their dose and complete treatment.

10. What is trastuzumab deruxtecan (T-DXd) and how does it relate to tucatinib?

Trastuzumab deruxtecan (T-DXd, brand name Enhertu) is an antibody-drug conjugate that has shown exceptional activity in HER2-positive metastatic breast cancer in the DESTINY-Breast trial series. It has become a preferred option in the treatment sequence. The relative positioning of T-DXd and tucatinib-based regimens continues to evolve as clinical trial data matures.

11. Can patients with brain metastases participate in breast cancer clinical trials?

Historically, clinical trials excluded patients with brain metastases, which limited the evidence base for treating this important subgroup. More recent trials — including HER2CLIMB and TransHERA — have specifically included patients with brain metastases and built intracranial endpoints into their design, reflecting a more inclusive and clinically appropriate approach to trial design.

12. Where can patients find information about clinical trials for HER2-positive breast cancer?

ClinicalTrials.gov is the US government’s registry of clinical trials, searchable by disease, treatment, location, and eligibility criteria. The National Cancer Institute (cancer.gov) also provides information about clinical trial participation. Oncologists specialising in breast cancer are the most important resource for understanding which trials may be appropriate for an individual patient’s specific situation.

Explore ideas that elevate your thinking with The Elevate Magazine.

Leave a Reply

Your email address will not be published. Required fields are marked *